SCHEMBL21361622

SCHEMBL21361622

CC(C)N1CCN(c2ccc(F)cc2Cl)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GAA P10253 2/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GRM5 P41594 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KDM4E B2RXH2 3/20 0.41
MAPT P10636 2/20 0.41
MAPK13 O15264 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
MAPK14 Q16539 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
RAD52 P43351 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8137240 0.85 ALDH1A1 (0.46) ALDH1A1L3MBTL1GAAHTTLMNA
SCHEMBL21361437 0.83 DRD2 (0.46) ALDH1A1L3MBTL1GAAHTTLMNA
SCHEMBL21965082 0.81 LMNA (0.45) ALDH1A1GAAHTTLMNAKDM4E
SCHEMBL19625789 0.81 ALDH1A1 (0.67) ALDH1A1L3MBTL1GAAHTTLMNA
SCHEMBL159067 0.80 MAPT (0.66) ALDH1A1L3MBTL1GAAHTTLMNA
SCHEMBL24755749 0.80 SLC6A2 (0.41) ALDH1A1L3MBTL1SLC6A2SLC6A4SLC6A3
SCHEMBL21361478 0.80 DRD2 (0.49) ALDH1A1L3MBTL1SMN1; SMN2KDM4EHTR6
SCHEMBL27195927 0.79 ALDH1A1 (0.51) ALDH1A1L3MBTL1GAAHTTLMNA
SCHEMBL28224399 0.77 ALDH1A1 (0.62) ALDH1A1L3MBTL1GAAHTTLMNA
SCHEMBL10819407 0.77 NPC1 (0.57) GAAHTTSMN1; SMN2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G ALDH1A1 4848/4885L3MBTL1 4760/4885GAA 1920/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G ALDH1A1 4834/4885L3MBTL1 4748/4885GAA 2080/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G ALDH1A1 4817/4885L3MBTL1 4721/4885GAA 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.